The new mRNA flu shot mFlusiva is more effective. Why doctors worry Long Islanders may not get it.

Key Points:

• The FDA has approved Moderna’s mFlusiva, an mRNA-based flu vaccine, for people aged 50 and older after studies showed it is 26.6% more effective than traditional flu vaccines in preventing symptoms.
• mFlusiva is only the second FDA-approved mRNA vaccine after COVID-19 vaccines and has the potential to save many lives by more closely matching circulating flu strains each season through faster development methods.
• Despite its benefits, vaccine distrust and misinformation about mRNA technology persist, with some public figures and segments of the population skeptical about its safety and effectiveness, potentially hindering widespread adoption.
• The FDA initially hesitated to review Moderna’s application for mFlusiva due to controversy and skepticism around mRNA vaccines, but reversed its decision following pressure from scientists and the pharmaceutical industry.
• Moderna is expanding mRNA vaccine research, including trials for an Ebola vaccine and cancer vaccines, while further studies on mFlusiva’s safety and efficacy continue for adults 65 and older.